Bleomycin: Uses, Intralesional Dosing, And Side Effects
Chemotherapy agent used intralesionally for resistant warts and other skin conditions with notable cutaneous side effects.
Bleomycin is an antibiotic derived from the fungus Streptomyces verticillus, primarily utilized as a chemotherapy agent due to its ability to induce DNA strand scission, thereby inhibiting cell replication. This mechanism disrupts rapidly dividing cells, making it effective against malignancies and certain proliferative skin lesions. Excreted mainly via the kidneys, bleomycin’s activity varies by tissue hydrolase levels, with skin notably lacking bleomycin hydrolase, leading to a high incidence of cutaneous adverse effects—approximately 50% in intravenous cancer therapy.
What is bleomycin?
Bleomycin comprises a family of glycopeptide antibiotics produced by Streptomyces verticillus, isolated in the 1960s. Its anticancer properties stem from forming a complex with ferrous ions and oxygen, generating free radicals that cleave DNA strands, preferentially affecting G-C rich regions. Unlike many chemotherapeutics, it demonstrates minimal myelosuppression but prominent pulmonary and dermatologic toxicity. FDA-approved for various carcinomas and lymphomas, its intralesional application in dermatology remains off-label, supported by clinical trials and case series demonstrating efficacy in refractory conditions.
Side effects of intravenous bleomycin
Intravenous bleomycin for systemic malignancies frequently induces dermatologic reactions due to absent hydrolase in keratinocytes. Common skin side effects include:
- Hyper pigmentation (generalized or flagellate pattern)
- Raynaud phenomenon
- Nail changes (discoloration, dystrophy)
- Palmar/plantar desquamation and painful fissures
- Alopecia
Less common effects encompass striae distensae, telangiectasia, and vasculitis-like eruptions. Flagellate erythema, characterized by linear, whip-like hyperpigmented streaks, is pathognomonic, arising 1 day to months post-administration. Systemic risks include pulmonary fibrosis (dose-dependent, >400 units cumulative) and hypersensitivity pneumonitis.
Approved uses
Bleomycin receives regulatory approval from FDA, Medsafe (New Zealand), and equivalents for:
- Squamous cell carcinoma (head/neck, cervix, penis, skin)
- Hodgkin and non-Hodgkin lymphoma
- Testicular cancer
- Malignant pleural effusion (intrapleural)
Administered intravenously, intramuscularly, or intrapleurally, poor oral bioavailability precludes that route. Combination regimens like BEP (bleomycin, etoposide, cisplatin) remain standard for germ cell tumors.
Intralesional bleomycin
In dermatology, intralesional bleomycin targets recalcitrant lesions, penetrating poorly through membranes but enhanced by local anesthetics or electroporation. Off-label status necessitates informed consent, though trials confirm safety and efficacy. Preparation involves dilution by chemotherapy-trained professionals to avert aerosol exposure.
What is it used for?
Primary indication: viral warts unresponsive to cryotherapy or salicylic acid, including immunocompromised patients (e.g., transplant recipients), periungual, mosaic plantar, and anogenital warts. Cure rates from placebo-controlled trials:
| Wart Site | Cure Rate (%) |
|---|---|
| Hand | 80–92 |
| Foot | 66–94 |
| Periungual | ~90 |
Other applications (case reports/trials): keloids (flattening in 80% Vietnamese cohort), basal cell carcinoma, cutaneous leishmaniasis, pyogenic granuloma, digital mucous cysts.
Preparation and dosing
Dilute bleomycin sulfate to 1 U/ml (1 mg/ml) in normal saline or 1% lidocaine (epinephrine-free). Stable refrigerated for 4 weeks. Debulk hyperkeratotic warts via paring. Employ 1 ml tuberculin syringe with 30G needle or insulin syringe.
Injection technique
Inject 0.1–0.3 ml per wart (max 1–2 units total/session), targeting blanching without overflow. Techniques include:
- Multiple punctures around base
- Intradermal fanning
- Electrochemotherapy: post-injection electrical pulses boost uptake (complete response 74–84% in tumors)
Sessions spaced 2–4 weeks; 1–3 suffice for warts.
Aftercare and response
Immediate: erythema, edema, pain (paracetamol/codeine; peaks 24–72 hours). Week 1–4: sterile pustules, black eschar formation signals necrosis. Eschar sloughs by 4 weeks, revealing healed skin. Non-responders require repeat. Microneedling variants reduce pain.
Side effects of intralesional bleomycin
Local: pain, swelling, Raynaud-like vasospasm, ulceration, scarring (rare). Systemic rare: anaphylaxis, urticaria, flagellate pigmentation (no pulmonary fibrosis reported). Contraindications: peripheral vascular/connective tissue disease, pregnancy/lactation (teratogenic in mice), Raynaud phenomenon.
Flagellate erythema
Linear hyperpigmentation mimicking whip marks, classic to bleomycin (also peplomycin, shiitake dermatitis). Arises from minor trauma releasing drug-laden keratinocytes.
Frequently asked questions
Is intralesional bleomycin FDA-approved for warts?
No, it’s off-label; obtain informed consent. Efficacy evidenced by trials.
How painful is bleomycin injection?
Moderately painful; lidocaine dilution and post-injection analgesics mitigate. Less with microneedling.
What do warts look like after treatment?
Blanching, then black scab (4 weeks); indicates success.
Can it cause cancer or lung damage locally?
No systemic absorption risks pulmonary fibrosis; DNA damage confined to lesion.
Suitable for children/immunosuppressed?
Yes, effective in recalcitrant cases; caution in vascular disease.
References
- Bleomycin – DermNet — DermNet NZ. 2023. https://dermnetnz.org/topics/bleomycin
- Flagellate Erythema – DermNet — DermNet NZ. 2023. https://dermnetnz.org/topics/flagellate-erythema
- Common Warts — Singer Dermatology. 2023. https://singerderm.com/common-warts/
- Electrochemotherapy – DermNet — DermNet NZ. 2023. https://dermnetnz.org/topics/electrochemotherapy
- Intralesional Agents in Dermatology: Pros and Cons — PMC – NIH. 2021-11-18. https://pmc.ncbi.nlm.nih.gov/articles/PMC8611707/
Similar Articles
Read full bio of Sneha Tete
